Our results therefore demonstrate that BTZ is a relatively poor combination partner to increase the cytotoxic effect of ibrutinib against MM or MCL cells, while CFZ, and in particular LU-102, show consistently strong synergistic cytotoxicity with ibrutinib. Here, BCAM is linked to Miyoshi myopathy.